



December 20, 2016

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2011-000631-92/ Novartis Protocol ID CQGE031A2208

A phase II, randomized, double-blind, placebo controlled, parallel design, dose ranging, multi-center trial of four levels of exposure of QGE031 s.c. for 16 weeks in subjects aged 18 years and older with peanut allergy

Trial CQGE031A2208 was cancelled with no patient enrollment and as such, no results will be reported.